利用美国食品药品监督管理局批准包数据开展快速网状Meta分析可行但存在局限
本研究旨在检验利用Drugs@FDA和ClinicalTrials.gov识别试验并作为系统评价与网状Meta分析证据基础的快速方法。研究检索文献数据库、Drugs@FDA和ClinicalTrials.gov中一线青光眼药物的合格试验,提取数据并评估偏倚风险,分别对每个来源识别的试验及三来源所有独特试验拟合随机效应网状Meta分析模型。共识别138项独特试验,纳入29,394名受试者,涉及15种一线青光眼药物。仅使用Drugs@FDA的试验可生成精度合理的效应估计和相似的相对排序,而仅使用ClinicalTrials.gov则不能。结论认为利用Drugs@FDA数据的快速网状Meta分析方法可行但有其局限性,药物批准包和ClinicalTrials.gov的试验设计与结果报告均可改进。
要点
- 共识别138项独特试验,纳入29,394名受试者,涉及15种一线青光眼药物。
- 仅使用Drugs@FDA的试验可生成精度合理的效应估计和相似的相对排序,仅使用ClinicalTrials.gov则不能。
- 药物批准包和ClinicalTrials.gov的试验设计与结果报告均可改进。
核心结论
- 利用Drugs@FDA数据的快速网状Meta分析方法可行但有其自身局限性。
- 药物批准包和ClinicalTrials.gov的试验设计与结果报告均可改进。
研究设计与样本
- 检索文献数据库、Drugs@FDA和ClinicalTrials.gov中一线青光眼药物的合格试验。
- 提取数据,评估偏倚风险,检查不同来源信息的完整性和一致性。
- 分别对每个来源识别的试验及三来源所有独特试验拟合随机效应网状Meta分析模型。
主要发现
- 共识别138项独特试验,纳入29,394名受试者,涉及15种一线青光眼药物。
- 对于同一试验,不同数据来源报告的信息有时不一致。
- 期刊文章提供系统评价所需信息最多,试验注册信息提供最少。
- 与纳入所有独特试验的网状Meta分析相比,仅使用Drugs@FDA的试验可生成精度合理的效应估计和相似的相对排序,仅使用ClinicalTrials.gov则不能。
局限性
- 利用Drugs@FDA数据的快速网状Meta分析方法可行但有其自身局限性。
- 药物批准包和ClinicalTrials.gov的试验设计与结果报告均可改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test rapid approaches that use Drugs@FDA (a public database of approved drugs) and ClinicalTrials.gov to identify trials and to compare these two sources with bibliographic databases as an evidence base for a systematic review and network meta-analysis (NMA). STUDY DESIGN AND SETTING: We searched bibliographic databases, Drugs@FDA, and ClinicalTrials.gov for eligible trials on first-line glaucoma medications. We extracted data, assessed risk of bias, and examined the completeness and consistency of information provided by different sources. We fitted random-effects NMA models separately for trials identified from each source and for all unique trials from three sources. RESULTS: We identified 138 unique trials including 29,394 participants on 15 first-line glaucoma medications. For a given trial, information reported was sometimes inconsistent across data sources. Journal articles provided the most information needed for a systematic review; trial registrations provided the least. Compared to an NMA including all unique trials, we were able to generate reasonably precise effect estimates and similar relative rankings for available interventions using trials from Drugs@FDA alone (but not ClinicalTrials.gov). CONCLUSIONS: A rapid NMA approach using data from Drugs@FDA is feasible but has its own limitations. Reporting of trial design and results can be improved in both the drug approval packages and on ClinicalTrials.gov.
引用
- Wang L, Rouse B, Marks-Anglin A, et al. Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations. J Clin Epidemiol. 2019. PMID: 31226413. doi:10.1016/j.jclinepi.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。